Avior Bio Inc.



 July 23, 2020

Avior Bio Receives Authorization to Initiate First-in-Human Phase 1 Pharmacokinetics, Safety and Tolerability Study with AV104 Buccal Films

 April 2, 2020

Avior Demonstrates Rapid Buccal Absorption within 10 minutes of Nalmefene Using Speedit™ Film Technology platform as a Medical Countermeasure for the Reversal of Opioid-Induced Respiratory Depression in a Beagle Dog Model  


December 12, 2019
Avior Demonstrates Significantly Superior Bioavailability of AV103 films as Compared to Commercial Selincro® in a Beagle Dog Model

September 19, 2019

Sono-Tek Enters Into Agreement With Avior Bio Inc


July 22, 2019 
Avior files PCT Patent Application for its Speedit™ formulation and method of manufacturing.


July 12, 2019
Avior Signs Clinical Manufacturing Deal with Protoform Inc.

March 8, 2019

National Institute of Health Awards Avior’s First Phase 1 SBIR Grant – “A Novel Fast Acting Nalmefene Film for the Treatment of Opioid Overdose”

January 3, 2019
Avior establishes a developmental laboratory at the Biolabs’ Innovation Center in downtown, Durham, NC.  


November 24, 2018
Avior signs a strategy small-business research loan with North Carolina Biotechnology Center.

October 25, 2018
Avior files Patent Application – 870/3 PROV titled – Method and Device of Treating Chronic Kidney Disease associated Pruritus.

September 14, 2018
Avior develops its first prototype formulation using Speedit™ transmucosal delivery

May 02, 2018

Avior and Quality Chemical Laboratories (QCL) Enter Partnership a $1 Million Investment     

April 12, 2018

Avior Demonstrates that AV104 Significantly Suppresses Substance P Induced Pruritus in a Well Established C57BL Rodent Pharmacodynamic Model

Feb 22, 2018
Avior files for Incorporation in the State of North Carolina